Stockreport

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF convenience over first-generation anti-IL-23 monoclonal antibodies Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipated in the sec [Read more]